scholarly journals Risk Factors for Opioid-induced Constipation in Cancer Patients: a Single-institution, Retrospective Analysis

2021 ◽  
Author(s):  
Yuko Kanbayashi ◽  
Yuichi Ishizuka ◽  
Mayumi Shimizu ◽  
Shohei Sawa ◽  
Katsushige Yabe ◽  
...  
Keyword(s):  
Risk Factors ◽  
Regression Analysis ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Pain Treatment ◽  
Advanced Cancer Patients ◽  
Characteristic Analysis ◽  
Patients With Cancer ◽  
Laxative Effect ◽  
Ordered Logistic Regression

Abstract Purpose: To identify risk factors for opioid-induced constipation (OIC).Methods: This study retrospectively analysed 175 advanced cancer patients who were receiving pain treatment with opioids and were newly prescribed laxatives for OIC at Seirei Hamamatsu General Hospital between November 2016 and June 2021. For the regression analysis of factors associated with OIC, variables were extracted manually from medical charts. The effect of laxatives was evaluated 3 days after administration. The effect of laxatives was evaluated based on whether the OIC was improved. The OIC was defined based on Rome IV diagnostic criteria. Multivariate ordered logistic regression analysis was performed to identify risk factors for OIC. Optimal cut-off thresholds were determined using receiver operating characteristic analysis. Values of P < 0.05 (two-tailed) were considered significant. Results: Significant factors identified included body mass index (BMI) (odds ratio [OR] = 0.141, 95% confidence interval [CI] = 0.027–0.733; P = 0.020), chemotherapy with taxane within 1 month of evaluation of laxative effect (OR = 0.255, 95%CI = 0.068–0.958; P = 0.043), use of naldemedine (OR = 2.791, 95%CI = 1.220–6.385; P = 0.015) and addition or switching due to insufficient prior laxatives (OR = 0.339, 95%CI = 0.143–0.800; P = 0.014).Conclusion: High BMI, chemotherapy including a taxane within 1 month of evaluation of laxative effect, no use of naldemedine and addition or switching due to insufficient prior laxatives were identified as risk factors for OIC in advanced cancer patients with cancer pain.

Methylphenidate (MP) and nursing telephone intervention (NTI) for cancer-related fatigue (CRF) in advanced cancer patients: A double-blind randomized phase II trial.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 9023-9023
Author(s):  
Eduardo Bruera ◽  
Sriram Yennurajalingam ◽  
Pedro Emilio Perez-Cruz ◽  
David Hui ◽  
Susan Frisbee-Hume ◽  
...  
Keyword(s):  
Regression Analysis ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Mixed Model ◽  
Rank Test ◽  
Telephone Intervention ◽  
Advanced Cancer Patients ◽  
Significant Difference ◽  
Edmonton Symptom Assessment Scale ◽  
Longitudinal Regression

9023 Background: CRF is the most common and distressing symptom in advanced cancer patients. Preliminary studies support MP and NTI for CRF (Bruera et al. JCO 2006). The primary objective of our study was to determine the effect of MP as compared to placebo (P). A secondary objective was to investigate the role of NTI as compared to control telephone intervention (CTI). Methods: Advanced cancer patients with fatigue ≥4/10 on the Edmonton Symptom Assessment Scale (ESAS), normal cognition, no evidence of major depression and hemoglobin ≥8 were eligible. Patients were randomized to 4 groups in a 2x2 factorial design (MP+NTI, P+NTI, MP+CTI and P+CTI). Primary endpoint was Functional Assessment of Chronic Illness-Fatigue (FACIT-F) subscale scores between day 15 and baseline. The dose and duration of methylphenidate was 5 mg every two hours, as needed, up to 20 mg/day. We tested the median difference in FACIT-F subscale scores between the groups using the Kruskal Wallis test and Wilcoxon signed rank test. Longitudinal regression analysis was conducted with a mixed model. Results: Total accrual was 197. Mean (SD) age was 58 (12), female 67% (N=148), white 72% (N=136), gastrointestinal cancers were the most common 22% (N=41). Baseline FACIT-F subscores were similar among the 4 groups. The median FACIT-F subscores showed significant improvement between Day 15 and baseline for all four groups except for P+CTI (Table): MP+NTI (4.5, P=0.004), P+NTI (8, P<0.001), MP+CTI (7, P<0.001), and P+CTI (5, P=0.06), with no statistically significant difference between MP and P (6 vs. 6, P=0.89). Longitudinal regression analysis showed a time effect (P<0.001) and group differences for NTI vs. CTI with FACIT-F (P=0.13) and ESAS (P=0.03). Grade 3 toxicities were similar between the MP and P arms (34/93 vs. 24/97, P=0.09). Conclusions: MP was not effective as compared to P for CRF in advanced cancer patients. NTI may be effective and should be further studied. [Table: see text]

Perception of curability in an international cohort of advanced cancer patients receiving palliative care.

2016 ◽  
Vol 34 (26_suppl) ◽  
pp. 5-5
Author(s):  
Sriram Yennu ◽  
Omar M. Shamieh ◽  
Luis Fernando Rodrigues ◽  
Columbe Tricou ◽  
Marilène Filbet ◽  
...  
Keyword(s):  
Palliative Care ◽  
Logistic Regression ◽  
Regression Analysis ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Logistic Regression Analysis ◽  
Performance Status ◽  
Advanced Cancer Patients ◽  
Education Performance ◽  
Understanding Of Illness

5 Background: There is limited data on the illness understanding and perception of cure among advanced cancer patients (ACP) receiving palliative care around the world. The aim of the study was to determine the frequency and factors associated with perception of curability in countries in North and South Americas , Europe, Asia and Africa. Methods: Secondary analysis of a study to determine the decisional control preferences in different countries. ACP receiving palliative care were surveyed to assess the patients’ Understanding of Illness using a Understanding Of Illness questionnaire. Descriptive statistics and Logistic regression analysis were performed. Results: A total 1390 ACPs were evaluated. The median age was 58, 55% were female, 59% were married, 47% were catholic, 36.2% were educated college or higher degree. 681/1390 (49%) reported that their cancer is curable, 60% felt perceived that the goals of therapy was “to get rid of their cancer,” 79% perceived that the goals of the therapy was to “make them feel better.” 62 % perceived they were relatively healthy. Logistic regression analysis (Table 1) shows that better Karnosfsky performance status (OR 1.009, P = 0.04), higher education (OR 0.52, P = 0.0001), ACP's belonging to Brazil, France and S. Africa were less likely and ACPs from Philippines, Jordan were more likely to have a perception of curability. Age, gender, marital status, religion and passive decision control preferences were not significantly associated with perception of curability. Conclusions: The perception of curability in ACP's is 49% and significantly differs by education, performance status, and country of origin. Integration of Palliative Care can be more complex in these patients. Further studies are needed to develop strategies to reduce this misperception so as to have early integration of palliative care. [Table: see text]

Risk factors for developing osteonecrosis of jaw in advanced cancer patients underwent zoledronic acid treatment

2019 ◽  
Vol 15 (30) ◽  
pp. 3503-3511 ◽  
Author(s):  
Wei-Xiang Qi ◽  
Shengguang Zhao ◽  
Jiayi Chen
Keyword(s):  
Risk Factors ◽  
Logistic Regression ◽  
Zoledronic Acid ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Regression Analyses ◽  
Multivariate Logistic Regression ◽  
Advanced Cancer Patients ◽  
Factors Associated ◽  
Osteonecrosis Of Jaw

Aim: To investigate the risk factors for developing osteonecrosis of jaw (ONJ) in advanced cancer patients with bone metastases underwent zoledronic acid (ZA) treatment. Materials & methods: Univariate and multivariate logistic regression analyses were performed to investigate factors associated with developing ONJ in advanced cancer patients. Results: A total of 2214 advanced cancer patients were included. Univariate and multivariate logistic regression analyses for risk factors associated with ONJ were older age (≥66 years, hazards ratio [HR]: 3.21; p = 0.007), anemia (HR: 3.29; p = 0.006) and duration of ZA exposure (between 1 and 2 years, HR: 3.91, p = 0.01; ≥2 years, HR: 8.07, p < 0.001), respectively. Conclusion: Patients with older age, anemia and/or more than 1 year of ZA treatment are at high risk of developing ONJ.

scholarly journals Predictors for development of denosumab-induced hypocalcaemia in cancer patients with bone metastases determined by ordered logistic regression analysis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yuko Kanbayashi ◽  
Koichi Sakaguchi ◽  
Fumiya Hongo ◽  
Takeshi Ishikawa ◽  
Yusuke Tabuchi ◽  
...  
Keyword(s):  
Logistic Regression ◽  
Regression Analysis ◽  
Cancer Patients ◽  
Serum Calcium ◽  
Logistic Regression Analysis ◽  
Advanced Cancer Patients ◽  
Roc Curve Analysis ◽  
Ordered Logistic Regression ◽  
Pre Treatment ◽  
Clinical Records

AbstractThis retrospective study was undertaken to identify predictors for the development of hypocalcaemia even with prophylactic administration of calcium and vitamin D, and to help guide future strategies to improve the safety, efficacy, and QOL of patients receiving denosumab. Between January 2016 and February 2020, a total of 327 advanced cancer patients at our hospital who were receiving denosumab were enrolled. Variables associated with the development of hypocalcaemia were extracted from the clinical records. The level of hypocalcaemia was evaluated using CTCAE version 5. Multivariate ordered logistic regression analysis was performed to identify predictors for the development of hypocalcaemia. Optimal cut off thresholds were determined using ROC analysis. Values of P < 0.05 (2-tailed) were considered significant. 54 patients have developed hypocalcemia (≥ Grade 1). Significant factors identified included concomitant use of vonoprazan [odds ratio (OR) = 3.74, 95% confidence interval (CI) 1.14–12.26; P = 0.030], dexamethasone (OR = 2.45, 95%CI 1.14–5.42; P = 0.022), pre-treatment levels of serum calcium (OR = 0.27, 95%CI 0.13–0.54; P < 0.001), ALP/100 (OR = 1.04, 95%CI 1.01–1.07; P = 0.003), and haemoglobin (OR = 0.79, 95%CI 0.68–0.93; P = 0.004). ROC curve analysis revealed that the threshold for pre-treatment levels of serum calcium was ≤ 9.3 mg/dL, ALP was ≥ 457 U/L, and haemoglobin was ≤ 10.4 g/dL. In conclusion, concomitant use of vonoprazan or dexamethasone, and pre-treatment levels of serum calcium (low), ALP (high) and haemoglobin (low) were identified as significant predictors for the development of denosumab-induced hypocalcaemia.

Sign in / Sign up

Export Citation Format

Share Document